Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation

Area of Science:

• Biotechnology and pharmaceutical sciences
• Nanomedicine and drug delivery systems
• Immunology and vaccinology

Background:

• Lipid nanoparticles (LNPs) are crucial for mRNA delivery, with polyethylene glycol (PEG) being a standard component for stability.
• Growing evidence indicates PEG's immunogenicity, necessitating the exploration of alternative polymers for next-generation mRNA therapeutics.
• Poly(2-methyl-2-oxazoline) (PMOZ) is investigated as a potential replacement for PEG in LNP formulations.

Purpose of the Study:

• To evaluate the suitability of PMOZ as a PEG alternative in LNP-based mRNA delivery systems.
• To compare the properties and bioactivities of PMOZ-containing LNPs with traditional PEG-based LNPs.
• To assess the impact of PMOZ percentage and density on transfection efficiency and immune responses.

Main Methods:

• Formulation of LNPs with varying percentages and densities of PMOZ.
• Comparison of PMOZ-LNPs against PEG-LNPs for mRNA delivery efficiency.
• In vivo assessment of antigen-specific T-cell and antibody responses induced by PMOZ-LNPs.

Main Results:

• Decreasing PMOZ percentage improved transfection efficiency and immunostimulatory potential.
• Reduced PMOZ density enhanced antigen-specific T-cell responses in vivo, but not antibody responses.
• PMOZ-LNPs induced superior neutralizing antibody titers compared to PEG-LNPs, while PEG-LNPs elicited stronger CD8+ T-cell responses.

Conclusions:

• PMOZ demonstrates potential as a viable alternative to PEG in LNP formulations for mRNA delivery.
• Tailoring PMOZ content and density can modulate immune responses, offering a strategy for vaccine development.
• Further development of PMOZ-based LNPs could lead to improved mRNA therapeutics with reduced immunogenicity concerns.